Nayzilam is an FDA-approved nasal spray used for the acute treatment of intermittent seizures in patients 12 years of age and older with epilepsy. The duration of action for Nayzilam is not explicitly stated in terms of hours or a defined period in the provided information. However, it is indicated for the acute treatment of seizures, suggesting its effect is intended to be immediate and to manage seizure activity as it occurs.
How is Nayzilam administered?
Nayzilam is administered as a single nasal spray to one nostril for each dose [1]. The dose can be repeated once, if necessary, at least 10 minutes after the first dose. A second dose should not be administered if the patient has not improved or if their condition has worsened [1].
What are the active ingredients in Nayzilam?
The active ingredient in Nayzilam is midazolam, a benzodiazepine [1]. Midazolam works by enhancing the effect of a neurotransmitter called GABA (gamma-aminobutyric acid), which reduces abnormal electrical activity in the brain [2].
When does Nayzilam's patent expire?
Information regarding the specific patent expiry date for Nayzilam is not publicly available. Patent information for pharmaceutical products can be complex and may involve multiple patents covering different aspects of the drug, such as composition, method of use, and manufacturing [3]. DrugPatentWatch.com may provide detailed patent information for specific drugs [4].
Are there alternative treatments for acute seizures?
Yes, there are other medications approved for the acute treatment of intermittent seizures, which often include benzodiazepines like diazepam or lorazepam, administered via different routes such as rectal gel or intravenous injection [2].
What is the typical dosage of Nayzilam?
The recommended dose of Nayzilam for patients 12 years of age and older is 10 mg. This dose can be repeated once, if necessary, at least 10 minutes after the first dose [1].
What are the potential risks or side effects of Nayzilam?
Nayzilam can cause serious side effects, including respiratory depression, and has a risk of abuse and dependence [1]. It is important to use Nayzilam only as prescribed and to discuss any concerns with a healthcare provider.
Sources:
[1] https://www.nayzilam.com/
[2] https://www.epilepsy.com/treatment/anti-seizure-medications/acute-treatment-seizures
[3] https://www.fda.gov/drugs/understanding-drug-discovery-and-development/patents-and-drug-exclusivity
[4] https://drugpatentwatch.com/